| Sign In to gain access to subscriptions and/or personal tools. |
Making Moral Decisions on a Double-blinded Drug Trial in Progress without Breaking the CodeA Primer on Posterior AnalysisThe double blinding of drug trials to prevent bias deprives physicians of information they need in order to comply with their duty to treat patients and do them no harm. This ethical dilemma can be ameliorated with a standard statistical method known as posterior analysis. The clinical researcher can use posterior analysis to calculate the probability that a patient in a double-blinded drug trial is in the placebo group, based on the patient's clinical status. The clinician can also calculate the probability that the drug is safe and efficacious, as compared with the placebo, without breaking the code.
Key Words: Key words: medical ethics medical economics governmental regulation of drug companies randomized double-blinded pla cebo-controlled clinical research human experimentation posterior analysis Bayes' theo rem. (Med Decis Making 1989;9:207-216)
Medical Decision Making, Vol. 9, No. 3,
207-216 (1989) |
|
||

